Future delivery systems for apomorphine in patients with Parkinson's disease.
van Laar
T
T
Department of Neurology, Leiden University, The Netherlands.
Van der Geest
R
R
Danhof
M
M
D000279:Administration, Cutaneous; D000281:Administration, Intranasal; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D001058:Apomorphine / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D004058:Diffusion; D016503:Drug Delivery Systems / Q000639:trends*; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D007478:Iontophoresis; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D013488:Suppositories
D000978:Antiparkinson Agents; D013488:Suppositories; D001058:Apomorphine